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Introduction: The relationship between peripheral tissue characteristics and pain symptoms in soft tissue
inflammation is poorly understood. The primary aim of this study was to determine immunohistochemical differences
in tissue obtained from patients with persistent pain and patients who had become pain-free after surgical treatment
for rotator cuff tendinopathy. The secondary aim was to investigate whether there would be differences in
glutaminergic and inflammatory gene expression between disease-derived and healthy control cells in vitro.
Methods: Supraspinatus tendon biopsies were obtained from nine patients with tendon pain before shoulder surgery
and from nine further patients whose pain had resolved completely following shoulder surgery. Histological
markers relating to the basic tendon characteristics, inflammation and glutaminergic signalling were quantified by
immunohistochemical analysis. Gene expression of glutaminergic and inflammatory markers was determined in
tenocyte explants derived from painful rotator cuff tendon tears in a separate cohort of patients and compared to
that of explants from healthy control tendons. Dual labelling was performed to identify cell types expressing
nociceptive neuromodulators.
Results: Tendon samples from patients with persistent pain demonstrated increased levels of metabotropic glutamate
receptor 2 (mGluR2), kainate receptor 1 (KA1), protein gene product 9.5 (PGP9.5), CD206 (macrophage marker) and
CD45 (pan-leucocyte marker) versus pain-free controls (p <0.05). NMDAR1 co-localised with CD206-positive cells,
whereas PGP9.5 and glutamate were predominantly expressed by resident tendon cells. These results were validated
by in vitro increases in the expression of mGluR2, N-methyl-D-aspartate receptor (NMDAR1), KA1, CD45, CD206 and
tumour necrosis factor alpha (TNF-α) genes (p <0.05) in disease-derived versus control cells.
Conclusions: We conclude that differences in glutamate receptors and inflammatory cell numbers are associated with
the resolution of shoulder pain in rotator cuff tendinopathy, and that disease-derived cells exhibit a distinctly different
neuro-inflammatory gene expression profile to healthy control cells.* Correspondence: bendean1979@gmail.com
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Musculoskeletal pain is a common and costly healthcare
problem affecting a third of the population. Shoulder
pain is the third most common cause of musculoskeletal
pain in the community and approximately 1 % of adults
consult a general practitioner with new shoulder pain
annually [1]. The majority of shoulder pain is associated
with rotator cuff tendinopathy (RCT) [2, 3]. Tendon pain
is more common in people with rotator cuff tears than
those with normal tendons [4], however there is a poor as-
sociation between the severity of symptoms and extent of
structural change [5, 6] and current non-operative strat-
egies are focused on steroid-based therapies with mixed
results. There is a need to better understand the role of
the peripheral tissue in tendinopathy-related pain to in-
form novel therapeutic options, possible pathways involve
the glutaminergic and inflammatory systems [7–10].
Glutamate is an important amino acid involved in
many key physiological processes including cell metabol-
ism, pain sensitisation and collagen synthesis [11, 12].
Much of the literature has been limited due to the lack
of availability of biologically representative control tissue.
The inability to gather tendon-matched and age-matched
control tissue from live donors has been a significant lim-
iting factor in many previous studies [13]. The first aim of
this study was to investigate whether there were histo-
logical differences relating to the glutaminergic and in-
flammatory systems between painful and pain-free human
supraspinatus tendons; these tendons being appropriately
matched in terms of both tendon macrostructure and pa-
tient demographics. We hypothesised that there would be
significant neuro-inflammatory differences between these
groups. The second aim was to investigate whether there
would be differences in glutaminergic and inflammatory
gene expression between rotator cuff tendon tear-derived
and healthy control cells. We hypothesised that disease
cells would have a significantly different gene expression
profile compared to control cells.
Methods
Analysis of pathological human supraspinatus tissue
Tendinopathic cohorts: painful and pain-free groups
All patients were initially referred to a specialist upper
limb clinic, after failing conservative management that
included a minimum of one bursal steroid injection, and
a course of physiotherapy or a home exercise programme.
All patients were diagnosed with RCT by the clinical
evaluation of a senior consultant shoulder surgeon. Pa-
tients were excluded if there was a full-thickness rotator
cuff tear, any other significant shoulder pathology not in-
volving the rotator cuff (osteoarthritis, frozen shoulder, in-
stability, or previous fracture), more than three previous
glucocorticoid injections, a glucocorticoid injection within
6 weeks of the treatment intervention and systemic steroiduse. Structural integrity of the rotator cuff was assessed
ultrasonographically in all patients and also by the operat-
ing surgeon at the time of surgery. All ultrasound scans
were performed by an individual trained using a specific
validated protocol that has been proven to be reliable [14].
Patients completed the Oxford Shoulder Score (OSS)
[15], a well-validated and widely used clinical outcome
measure. The OSS is a self-administered questionnaire
validated for the study of shoulder pain. The OSS was
originally designed for pre- and post-surgical outcomes
and in terms of content, it has questions related both to
pain and function. In terms of construct validity, it has
been well validated against other scoring systems as a
shoulder-specific questionnaire specifically for studying
rotator cuff tears. For this study any non-perfect OSS was
classified as symptomatic or ‘painful’ and perfect scores
‘pain-free’ or asymptomatic.
Supraspinatus tendon biopsies were taken from nine
patients undergoing subacromial decompression (SAD)
surgery (painful group) and from nine patients 5 years
or more after undergoing SAD surgery in whom pain
had resolved completely (pain-free group). Pain was
judged to have completely resolved if a full OSS of 48 was
documented; a full score is only possible if the patient re-
ports no pain symptoms over the previous 4 weeks. Of
note, all patients in the pain-free group had had significant
pain before their surgery was performed as evidenced by a
median OSS of 24 (range 20–40) pre-SAD. Ethical ap-
proval for this study was granted by the local research eth-
ics committee (Oxfordshire REC B ref: 09/H0605/111 and
Oxfordshire REC B ref: 12/SC/0028) and full informed
consent (according to the Declaration of Helsinki) was ob-
tained from all patients.
Tendon biopsy technique
A percutaneous ultrasound-guided core biopsy tech-
nique was used to acquire the supraspinatus tendon tis-
sue samples in the painful and pain-free patient groups.
This validated technique is described in more detail else-
where [16], and in brief, samples were collected just pos-
terior to the leading edge of the supraspinatus tendon.
This tendon sample is within 1 cm of the bony insertion
of supraspinatus onto the greater tuberosity. One biopsy
specimen was obtained per patient and each biopsy was
approximately 2 mm by 2 mm by 5 mm in size. Biopsies
were immediately placed into 10 % buffered formalin, sub-
sequently wax embedded and sectioned (4 μm) using a
microtome (Leica Microsystems Ltd, Milton Keynes, UK).
Histology and immunohistochemical procedures
A haematoxylin and eosin (H&E) stain was performed
on samples from every patient to assess the general char-
acteristics of the tissue samples and to confirm that they
were tendon (Fig. 1). Tissue sections were taken through
Fig. 1 Basic histology was similar in the pain-free and painful groups. Photomicrographs show the haematoxylin and eosin staining in the rotator
cuff tendon in the painful (a, b, c, d) and pain-free (e, f, g, h) groups. Scale bars: 40 μm
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mated PT Link (Dako, Glostrup, Denmark). All antibody
staining was performed using the EnVision FLEX™ visual-
isation system with an Autostainer Link 48 (Dako) accord-
ing to the manufacturer’s instructions. Antibody binding
was visualised using the FLEX™ 3,3’-diaminobenzidine
(DAB) substrate working solution. Isotype control staining
was also performed. To investigate the cell types express-
ing nociceptive neuromodulators in sections of patho-
logical supraspinatus, dual-labelling immunofluorescence
was performed with the macrophage marker CD206 and
type B synoviocyte and nerve marker protein gene prod-
uct 9.5 (PGP9.5), glutamate or N-methyl-D-aspartate re-
ceptor (NMDAR) 1. Details of antibodies used and their
working concentrations, as well as all staining protocols
can be found in the supplementary material (Appendix 1
in Additional file 1).
The assessment of the microscopic appearance of the
slides immunostained with DAB was undertaken by a
single blinded investigator. A Nikon inverted microscope
(Nikon, Tokyo, Japan) using Axiovision software (Carl
Zeiss, Jena, Germany) was used to capture images start-
ing at one corner of the tissue moving systematically in
a horizontal–vertical–horizontal manner until the tissue
section was exhausted using ×100 magnification with oil
immersion. A minimum of ten images were captured for
each tissue section. Each antibody set was imaged using
the same exact light intensity at the same sitting. The as-
sessment of the microscopic appearance of the slides
was undertaken using ImageJ® (National Institutes of
Health, Bethesda, MD, USA) using validated methods to
count cells and quantify staining, which have been
described in detail elsewhere [8, 17]. Methods to quan-
tify staining demonstrate good intra-observer (interclasscorrelation coefficient (ICC) = 0.830 at 1 month) and
inter-observer reliability (ICC = 0.724–0.909) [17]. While
cell-counting methods also demonstrated good intra-
observer (ICC = 0.953 at 1 month) and inter-observer reli-
ability (ICC = 0.970). Vascularity was measured using
manual vessel counts of the CD34-stained sections (ICC =
0.921). Modified Bonar scores were also calculated using a
scoring system based on the original scoring system and
our group’s recent work [8, 18]; this is described in the
online supplementary material (Appendix 2 in Additional
file 1).
Ex vivo analysis of disease-derived cells from a separate
patient cohort and healthy control cells
Cell explant and analysis
Tendon tissue was obtained from the Oxford Musculo-
skeletal BioBank (Oxford REC C 09/H0606/11) and was
collected with informed donor consent in full compli-
ance with national and institutional ethical require-
ments, the United Kingdom Human Tissue Act, and the
Declaration of Helsinki. Human tendon-derived cells
were isolated by the explant culture of both rotator cuff
tendon excised as part of debridement before tendon re-
pair and hamstring tendon excess to requirements for
autograft repair for anterior cruciate ligament rupture as
previously described [19]. The rotator cuff tendon was
taken from four male and three female patients with
symptomatic rotator cuff tears (mean age 50 years +/−
11). The median duration of symptoms in the rotator cuff
tear group was 12 months (range 6–24 months). The
hamstring tendon was harvested from two healthy male
and three female patients (mean age 27 years +/− 9).
Tenocytes were cultured in Dulbecco’s modified Eagle’s
medium (DMEM)-F12 containing 10 % fetal bovine serum
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37 °C and 5 % CO2. Cells were fed regularly every 2–3
days. RNA extraction was then carried out when passage
2 cells were at 80 % confluence 1 day after feeding.
RNA extraction and cDNA synthesis
Cells were treated with TRIzol® Reagent (Life Technolo-
gies) and the samples were stored at −80 °C. RNA was
then extracted using the Direct-zol™ RNA MiniPrep kit
(Zymo Research, Irvine, CA, USA) according to the
manufacturer’s instructions. This protocol included in-
column DNase I digestion. The quality of the RNA was
then tested using the NanoDrop 1000 spectrophotom-
eter (Fisher Scientific, Loughborough, UK) prior to the
samples being stored at −80 °C. The ratio of absorbance
of 260 nm and 280 nm was used to determine the purity
with all samples achieving a minimum of 1.80. Comple-
mentary DNA (cDNA) was synthesized using the tran-
scriptor first-strand cDNA synthesis kit (Roche, Welwyn
Garden City, UK) and was then stored at −20 °C until
further use.
Measurement of gene expression by quantitative RT-PCR
Real-time quantitative PCR were performed using the
ViiA™ Real-Time PCR system (Fisher Scientific), a Fast
SYBR® Green PCR kit (Life Technologies) and QuantiTect
Primer Assays (Qiagen, Hilden, Germany), as well as
validated assays designed by Primerdesign (Southampton,
UK). Primer details and sequences are listed in the online
supplementary material (Appendix 3 in Additional file 1).
Samples without reverse transcriptase served as negative
controls in real-time PCR to exclude genomic DNA con-
tamination. No-template control was included to indicate
there was no contamination in real-time PCR reagents.
Samples were run in triplicate with a coefficient of vari-
ation between duplicates of <1.0 cycle, and the average
value was used for analysis. A total of 250 ng of cDNA
was used in each reaction whose volume was in total
20 μL. A total of 5 μL of cDNA was used within the total
reaction volume of 20 μL. Standard curves were created
for all genes measured and a set threshold of 0.15 was
used for all calculations of relative gene expression.
Relative quantification is expressed as 2ΔCt, where ΔCt
is Ct (target gene) – Ct(TBP). Two housekeeping genes
were used (TBP and β-actin) and results were consistent
using both.
Statistical analysis
Statistical analysis was carried using GraphPad Prism
version 5.00 for Windows (GraphPad Software, San Diego,
CA, USA). Histograms for all data sets were analysed.
Data was normally distributed unless otherwise stated. Re-
sults are expressed as mean ± standard deviation unless
otherwise stated. Unpaired t tests and Mann-WhitneyU tests were used to test for differences between two
groups for parametric and non-parametric data respect-
ively. Statistical significance was set at a level of p <0.05.
The Benjamini-Hochberg procedure was used to correct
for multiple testing where stated. A power calculation
(power = 0.8, α = 0.05, μ1 = 0.7, μ2 = 1.0, standard devi-
ation 0.25, two-sided test) was used to determine that a
sample size of n = 6 per group would be sufficient. Data
from previous histological studies by our group was used
to estimate the means and standard deviation used in this
calculation. Spearman correlation coefficients were calcu-
lated to test the relationships between cell surface marker
expression (CD206 for macrophages and PGP9.5 for type
B synoviocytes), cytokine expression and glutamate recep-
tor expression in the tendon tear-derived cells.Results
The age, gender and diseases characteristics of the pain-
ful and pain-free groups are shown in Table 1. The only
significant demographic difference between the groups
was presence of pain in the painful group and the ab-
sence of pain in the pain-free group as measured by the
OSS (p = 0.0002). There were also no significant histo-
logical differences between groups in terms of cellularity,
vascularity (vessel count) and proliferation (Table 2 and
Fig. 1).Neuro-inflammatory characteristics
Increased numbers of inflammatory cells were seen in the
painful group versus the pain-free group (Table 2 and
Fig. 2) as shown by the increased expression of the pan-
leucocyte marker (CD45), a type B synoviocyte and nerve
marker (PGP9.5) and a macrophage marker (CD206).
CD45 and CD206 stained individual cells and did not
stain whole vascular structures. NMDAR1 and PGP9.5
stained both individual cells and vascular structures. Of
note, PGP9.5 is also a nerve marker but no distinct nerve-
like structures could be reliably discriminated within the
biopsy sections.
There were specific differences in the expression of
glutaminergic markers between the painful and pain-free
groups (Table 2 and Fig. 3); metabotropic glutamate re-
ceptor (mGluR)2 and kainate receptor 1 (KA1) were in-
creased in the painful group, while mGluR7 was increased
in the pain-free group. mGluR2 and KA1 staining related
to individual cells as well as vascular structures. mGluR7
staining related solely to vascular structures. The KA1 and
mGluR2 staining related to vascular structures as well as a
sub-population of cells within the tendon. Dual-labelling
immunofluorescence showed NMDAR1 co-localised with
CD206-positive cells, whereas PGP9.5 and glutamate were
predominately expressed by CD206-negative cells (resi-
dent tendon cells) (Fig. 4).
Table 1 Data representing the demographics of the pain-free
and painful groups, quantification of the baseline questionnaires
and tendon structure
Pain-free group Painful group p value
Number 9 9 -
Age (mean) 52 (+/− 7.8) 51 (+/− 8.2) 0.72
Sex 6 M 3 F 7 M 2 F 1.0





Median length of symptoms
pre-SAD (months)
22 (6–48) 12 (12–18) 0.43
Median number of steroid
injections (range)
1 (1–3) 1 (1–4) 0.92
Oxford Shoulder Score
(range)
48 (48) 32 (23–36) 0.0002***
All data is represented as median (interquartile range) or mean +/− standard
deviation unless otherwise stated. Statistical significance is denoted by
*p <0.05, **p <0.01, ***p <0.001 (between groups). PTT denotes
partial-thickness tear
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The relative expression of the glutaminergic genes
NMDAR1, KA1 and mGluR2 was significantly increased
in cells derived from tendon tears compared to healthy
control tendons (Fig. 5). mGluR7 gene expression was
not detected in either disease or control cells. The gene
expression of the metabotropic glutamate receptorsTable 2 Data representing the basic histological characteristics and
Pain-free group
Mean vessel count 1.09 (+/− 0.63)
Mean nuclei count 11.6 (+/− 4.1)
Median modified Bonar score 7.0 (6.5–8.0)
Proliferation (% PCNA staininga) 0.04 (0.03–0.06)
HIF1alphaa 0.01 (0.01–0.04)
VEGFa 0.27 (+/− 0.18)
CD45 (% cells positive) 6.8 (4.7–10)
CD206 (% cells positive) 13.2 (+/− 6.2)
Lactate dehydrogenasea 0.001 (0.0004–0.002)
Glutamatea 0.003 (0.001–0.03)
NMDAR1a 0.013 (0.006–0.015)





All data is represented as median (interquartile range) or mean +/− standard deviat
**p <0.01, ***p <0.001 (between groups).
HIF1alpha hypoxia-inducible factor 1-alpha, KA1 kainate receptor 1, mGluR metabot
proliferating cell nuclear antigen, PGP 9.5 protein gene product 9.5, VEGF vascular e
aDenotes per cell
bDenotes significant result after application of Benjamini-Hochberg proceduremGluR1 and mGluR5 was not different between groups,
although there was a trend towards increased expression
of mGluR5 in the tendon tear-derived cells (p = 0.07).
The relative expression of the inflammatory genes tumour
necrosis factor alpha (TNF-α), CD45 and CD206 was
significantly increased in tendon tear-derived cells versus
control (Fig. 4), while interleukin-1β expression was not
increased. There was no significant difference in extracel-
lular matrix gene expression between groups (collagen
type I alpha I chain (COL1A1), collagen type III alpha I
chain (COL3A1), aggrecan and decorin). There was no
difference in PGP9.5 (synoviocyte marker), PCNA (prolif-
erating cell nuclear antigen) and mTOR (mammalian tar-
get of rabamycin) gene expression between groups.
Correlation coefficients of gene expression data for
tendon tear-derived cells
Within the gene expression data related to cells derived
from rotator cuff tears there were strong correlations
between CD206 expression and glutamate receptor ex-
pression; KA1 (r = 0.96, p <0.0001), NMDAR1 (r = 0.76,
p = 0.002), mGluR1 (r = 0.83, p = 0.0002), mGluR2 (r =
0.95, p = 0.0002) and mGluR5 (r = 0.95, p = <0.0001).
There was no strong or significant correlation (r >0.4)
between PGP9.5 expression and glutamate receptor ex-
pression (r = 0.003, p = 0.86 for NMDAR1; r = 0.16,
p = 0.14 for KA1; r = 0.07, p = 0.38 for mGluR2). Therequantified immunohistochemistry
Painful group p value
0.80 (+/− 0.65) 0.47




0.06 (+/− 0.05) 0.004**b
12.4 (8.1–16.8) 0.038*









ion unless otherwise stated. Statistical significance is denoted by *p <0.05,
ropic glutamate receptor, NMDAR1 N-methyl-D-aspartate receptor, PCNA
ndothelial growth factor
Fig. 2 There were inflammatory differences between painful and pain-free rotator cuff tendons. Both the number of CD45 (pan-leucocyte marker)
and CD206 (macrophage marker) positive cells were increased in the painful group versus the pain-free group. LDH expression was increased in
the painful group, while VEGF was increased in the pain-free group. Photomicrographs depict the immunohistochemical staining of VEGF (a, e),
LDH (b, f), CD45 (c, g), CD206 (d, h), in the painful and pain-free groups. Scale bars: 40 μm. LDH lactate dehydrogenase, VEGF vascular endothelial
growth factor
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TNF-α expression (r = 0.97, p <0.0001), while there was
no strong or significant correlation between PGP9.5 ex-
pression and TNF-α expression.
Discussion
Both the in vivo and ex vivo components of this work
show that the glutaminergic and inflammatory pathways
are active in painful tendinopathy, despite there being noFig. 3 There were glutaminergic differences between painful and pain-free
was different between groups; mGluR2 and KA1 were increased in the pain
staining was exclusively of endothelial cells, while mGluR2 and KA1 staining
expression (type B synoviocyte marker) was increased in the painful group.
mGluR2 (a, e), mGluR7 (b, f), PGP 9.5 (c, g) and KA1 (d, h). Scale bars: 40 μm
PGP9.5 protein gene product 9.5significant differences in basic tendon histology between
painful and pain-free tendons. The close relationship be-
tween the glutaminergic and inflammatory systems was
further supported by the co-localisation of NMDAR1 and
CD206, as well as the significant correlations between glu-
tamate receptor and inflammatory gene expression.
There is little evidence in the literature relating histo-
logical changes in tissue to symptoms [20]. Tomita et al.
[21] showed that an increased neural density in therotator cuff tendons. The expression of several glutaminergic markers
ful group, while mGluR7 was increased in the pain-free group. mGluR7
was of both endothelial cells and resident tendon cells. PGP 9.5
Photomicrographs depict the immunohistochemical staining of
. KA1 kainate receptor 1, mGluR metabotropic glutamate receptor,
Fig. 4 Representative immunofluorescent images of torn human supraspinatus to show cell types expressing nociceptive neuromodulators. Panel
shows dual antibody labelling for CD206 (green) with (a) glutamate (violet), (b) PGP9.5 (violet) and (c) NMDAR1 (red). Cyan represents POPO-1
nuclear counterstain. NMDAR1 co-localised with CD206-positive cells, whereas PGP9.5 and glutamate were predominantly expressed by resident
tendon cells. Scale bar: 20 μm. mGluR metabotropic glutamate receptor, NMDAR N-methyl-D-aspartate receptor, PGP9.5 protein gene product 9.5
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der pain at rest. Gotoh et al. [22] demonstrated that
substance P levels in the subacromial bursa appeared to
correlate with pain levels as measured with a visual
analogue score. A significant limitation with these two
studies is the differences in gross structure that may ex-
plain the observed relationships with pain. The same
limitation is relevant to much work carried out on other
tendinopathies such as the Achilles and patellar, with
controls invariably having normal gross tendon structure
as opposed to the abnormal gross tendon structure fre-
quently seen in disease [20].
The role of inflammation in tendinopathy has been the
subject of significant controversy [7]. Some studies have
demonstrated that greater numbers of inflammatory
cells are present in tendinopathic than in healthy control
tissues [23, 24], while recent evidence has related these
inflammatory changes to patient symptomatology in the
Achilles [25]. Increased levels of inflammatory cytokines
such as interleukin-1β have repeatedly been demonstrated
in tendinopathy. We demonstrate increased numbers of
CD45 (pan-leucocyte) and CD206 (macrophage) positive
cells in painful versus pain-free tendons. Pro-inflammatory
markers TNF-α and CD45 were upregulated in disease
cells versus controls; therefore the findings of the present
study support the concept that inflammation contributes
to the pain symptomatology in tendinopathy.
The exact phenotype of the tendon-derived cells is un-
clear, but the pattern of gene expression (CD45/CD206/
TNF-α/PGP9.5) is consistent with the presence of a
significant proportion of ‘synoviocyte’-type cells. Type A
synoviocytes are resident macrophages and are also re-
ferred to as ‘fibrocytes’ [26, 27], they arise from mono-
cyte precursors and are consequently CD45 positive[28]. It is likely that type A synoviocytes make up a
proportion of the CD45- and CD206-positive cells seen
in the in vivo study but it is also possible that a signifi-
cant proportion of these cells migrate into tendon via
the bloodstream. The increase in PGP9.5 in the painful
group may relate to a subpopulation of type B synovio-
cytes (‘fibroblast-like synoviocytes’) as PGP9.5 has been
described as a marker of this population of cells in ani-
mals [29]. The cell markers expressed by ‘synoviocytes’
and other tissue fibroblasts are extremely fluid and com-
plex [30]. Emerging evidence points to the potential role of
the ‘synoviocyte’ in several chronic inflammatory disorders
[28] and this is supported by our findings. The level of
PGP9.5 gene expression was 14-fold higher than CD206
expression in the tendon tear-derived tendon cells, demon-
strating that type B synoviocytes are likely to be more
abundant in vitro than the type A macrophage-like cells.
Glutamate receptors can be broadly broken down into
two major types: ionotropic, which are glutamate-gated
ion channels (iGlu), and metabotropic, which are G-
protein coupled receptors that modulate signal trans-
duction cascades (mGlu) [31]. The ionotropic receptors
include kainate (KA) receptors, α-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid (AMPA) receptors
and N-methyl-D-aspartate (NMDA) receptors [32]. Gluta-
minergic changes have been described in painful tendino-
pathy, including an increase in extracellular glutamate
concentration and the upregulation of NMDA receptors
[8, 33, 34]. In the current study, the in vivo glutaminergic
changes involving the mGluR2, mGluR7 and KA1 recep-
tors alongside the metabolic change related to lactate de-
hydrogenase (LDH) are of interest; of note, both mGluR2
and KA1 gene expression were also upregulated in disease-
derived cells in vitro alongside NMDAR1. Interestingly
Fig. 5 Neuro-inflammatory genes are upregulated in cells derived
from rotator cuff tendon tears versus control cells. The expression
of the TNF-α (9.5-fold, p = 0.0009), CD45 (12.3-fold, p = 0.03), CD206
(2-fold, p = 0.004), NMDAR1 (3.5-fold, p = 0.003), KA1 (7.5-fold,
p = 0.049) and mGluR2 (205-fold, p = 0.0006) genes was significantly
increased in tendon tear-derived cells (a) proliferation, cell surface
markers and matrix genes (b) cytokine and glutaminergic genes
(n = 7 tendon tear-derived and 5 controls). The boxes represent
median +/− interquartile range, while the whiskers represent range.
Numbers in outlined boxes represent fold change in gene expression.
Statistical significance denoted by *p <0.05, **p <0.01, ***p <0.001.
KA1 kainate receptor 1, mGluR metabotropic glutamate receptor,
NMDAR N-methyl-D-aspartate receptor, TNF-α tumour necrosis
factor alpha
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inflammatory pain in mice [35], while peripheral mGluR2
agonism has analgesic properties in rats [36].
The co-localisation of NMDAR1 and CD206 suggests
that the non-neurovascular glutamate receptors are
predominantly located on the type A synoviocyte cell
population; while the absence of NMDAR1 and PGP9.5
co-localisation suggests that this is not the case for the
type B synoviocytes. This is further supported by the
correlations between the glutamate receptor expression
(KA1, NMDAR1, mGluR1, mGluR2 and mGluR5) and
CD206 expression, alongside the lack of correlation
between PGP9.5 expression and glutamate receptor ex-
pression. Therefore, it is highly likely that glutaminergic
signalling machinery is predominantly expressed by the
macrophage-like type A synoviocytes in vitro rather thanthe type B cells. The strong correlation between TNF-α
gene expression and CD206 infers that the TNF-α se-
creted in disease is largely produced by the type A syno-
viocytes although further work is required to support
this observation. PGP9.5 has been shown to co-localise
with NMDAR1 on nerves in tendinopathy [34]. Unfortu-
nately it was not possible to confirm this finding due to
the paucity of nerves within the biopsy sections.
It should be noted that the staining relating to both
KA1 and mGluR7 was to a large degree of vascular
structures. This is the likely explanation for the absence
of mGluR7 expression in explanted cells (fibroblasts likely
massively outnumber endothelial cells in vitro). The de-
creased mGluR7 staining previously demonstrated in ten-
don tears versus healthy control is also largely related to
endothelial cells and not the tendon cells [8]. In this study,
the result does not appear to be as a result of the potential
confounding factor vascularity, as this was not signifi-
cantly different between the groups. Little is known about
the role of mGluR7 in endothelial cell function but
mGluR7 is known to be expressed by rat endothelial cells
[37], while NMDA receptors are expressed by human
endothelial cells [38]. NMDAR activity is decreased by
mGluR7, inferring that the greater expression of mGluR7
in pain-free tendons may be representative of a less stress-
ful environment for the endothelial cells given NMDAR’s
potential pro-survival role [39]. The significant differences
in endothelial cell staining (mGluR7 and KA1) seen does
suggest that future research to investigate the role of
endothelial cells in tendinopathy may have great potential
in terms of better understanding disease pathogenesis.
The finding that ionotropic glutamate receptor agonism
increases inflammatory cytokine production [40–42] in
human synoviocytes and chondrocytes suggests that glu-
tamate receptor modulation may be a viable means of
therapeutically targeting the synoviocyte in painful tendi-
nopathy; this is consistent with our study’s finding in
terms of the co-localisation of NMDAR1 and CD206. The
kainate receptor has been implicated in the pathogenesis
of osteoarthritis and KAR antagonism has shown thera-
peutic in slowing down disease progression in animal
models [43]. It is worth adding that although this study fo-
cused primarily on the glutaminergic system, the signal-
ling systems relating to other neurotransmitters such as
acetylcholine and noradrenaline remain justifiable targets
for further investigation [44, 45].
A strength of this study is that the tendon samples
used for histological analyses were well matched in
terms of patient demographics and tendon macrostruc-
ture. Only a minority of studies have used supraspinatus
as a control and of these studies the vast majority have
used cadaveric supraspinatus tendon. Only four studies
have used supraspinatus from a live donor as a control
[46–49]; three of these used the supraspinatus of patients
Dean et al. Arthritis Research & Therapy  (2015) 17:176 Page 9 of 10who had sustained significant shoulder trauma and one
used supraspinatus from patients undergoing surgery for
shoulder instability [13]. To our knowledge this is the first
histological study that has used structurally and age-
matched tendon from pain-free tendinopathic patients as
a control. The histological findings of the study in terms
of protein expression have also been validated by the gene
expression results. A limitation of this study is that the
control cells used in the cell culture studies were not age-
matched with the disease cells and were from a function-
ally different tendon, hamstring. The observational nature
of our work means that any mechanisms underlying the
causality of changes observed can only be inferred and not
robustly proven. The cause of these tendon and cellular
differences cannot be determined given the study’s cross-
sectional design. The pain-free group had all had previous
subacromial decompression surgery prior to becoming
pain-free. This means that the tendon differences between
groups may be as a result of a true surgical treatment ef-
fect or the natural history of the disease. The mechanism
of the treatment effect after subacromial decompression
surgery is unclear [50, 51].
Conclusions
This study has shown that differences in specific glutam-
ate receptors (KA1/mGluR2/mGluR7) and inflammatory
cell numbers (CD45/CD206) are associated with the reso-
lution of pain in rotator cuff tendinopathy. These findings
improve our understanding of pain in tendinopathy and
may help identify novel therapeutic targets.
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